http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aac2ca691a7575179127ea355a620e58
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Rowinsky K. Rowinsky |
| name | Eric K Rowinsky Eric K. Rowinsky |
| given-name | Eric Eric K Eric K. |
| organization-name | Projections Research Inc, Phoenixville, Pa;The Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand;The Netherlands Cancer Institute and the Slotervaart Hospital, Amsterdam, The Netherlands;The University of Wisconsin, Madison, Wis;The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Tex;Glaxo SmithKline, Harlow and Collegeville, United Kingdom and Pa Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX From the Montefiore Medical Center/Albert Einstein College of Medicine, Bronx; New York University School of Medicine, New York, NY; Institute for Drug Development, San Antonio, TX; Beth Israel Deaconess Medical Center and Deaconess Medical Center, Boston, MA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; OSI Pharmaceuticals Inc, Boulder, CO; and Rush Cancer Institute, Chicago, IL From the Institute for Drug Development, Cancer Therapy and Research Center, and the University of Texas Health Science Center at San Antonio, San Antonio, TX; U.S. Oncology, and Baylor University Medical Center, Dallas, TX; and Pfizer Pharmaceuticals, Inc, Groton, CT. Authors' Affiliations: Departments of 1Antibody Technology & Immunology, 2Cell Biology, 3Preclinical Pharmacology, 4Molecule and Cell Engineering, 5Protein Science, 6Clinical Research, and 7Research, ImClone Systems, New York, New York 1Institute for Drug Development, Cancer Therapy and Research Center, Brook Army Medical Center and; 2The University of Texas Health Science Center, San Antonio, Texas; 3Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; 1Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio and Brooke Army Medical Center, San Antonio, Texas, and From the University of Michigan Medical School, Ann Arbor, MI; Cancer Therapy and Research Center, San Antonio, TX; Premiere Oncology of Arizona, Scottsdale, AZ; Abbott Laboratories, Abbott Park, IL; and Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, MA 2Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; From the Institute for Drug Development, Cancer Therapy and Research Center, and University of Texas Health Science Center at San Antonio, San Antonio, TX; Dana-Farber Partners in Cancer Care, Boston, MA; Cancer Institute of New Jersey, New Brunswick; Knoll Pharmaceutical Company, Mount Olive, NJ. From the Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio; and Brooke Army Medical Center, San Antonio, TX; GlaxoSmithKline, Collegeville, PA; and ImmunoGen Inc., Cambridge, MA. 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center; Institute for Drug Development, The Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, Texas, USA 1Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas; From the Institute for Drug Development, Cancer Therapy and Research Center; Department of Pharmacology and Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio; Brooke Army Medical Center; and Audie Murphy Veterans Administration Hospital, San Antonio, TX. 2Cancer Therapy and Research Centre, Institute for Drug Development, San Antonio, Texas; and 5ImClone Systems Incorporated, New York, New York 1Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas and From Christie Hospital and Royal Eye Hospital, Manchester, Queen Elizabeth Hospital and Birmingham and Midland Eye Centre, Birmingham, and AstraZeneca, Alderley Park, United Kingdom; Cancer Therapy Research Center, San Antonio, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; and AstraZeneca, Wilmington, DE. ImClone Systems Incorporated, New York, NY From The Johns Hopkins Oncology CenterBaltimore, MD; University of Alabama, Birmingham, AL; and Glaxo Wellcome, Inc, Research Triangle Park, NC. From the Institute for Drug Development, Cancer Therapy and Research Center; and the University of Texas Health Science Center, San Antonio, TX. Authors' Affiliations: 1Department of Oncology, Free University Hospital of Amsterdam, Amsterdam, the Netherlands; 2Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; and 3ImClone Systems Corporation, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ Authors' Affiliations: 1Institute For Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, Texas; and 2Eisai Incorporated, Woodcliff Lake, New Jersey From the Institute for Drug Development, Cancer Therapy and Research Center; and The University of Texas Health Science Center, San Antonio, TX. From the Institute for Drug DevelopmentCancer Therapy and Research Center; University of Texas Health Science Center; and Brooke Army Medical Center, San Antonio, TX; and Pharmaceuticals Division, Bayer Corporation, West Haven, CT. Stemline Therapeutics Inc. New York NY USA From the Institute for Drug Development, Cancer Therapy and Research Center, and Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, and MGI Pharma, Inc, Bloomington, MN. From ImClone Systems, Branchburg, NJ 1Institute for Drug Development, Cancer Therapy and Research Center, 1Institute For Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; Director, Institute for Drug Development of the Cancer Therapy and Research Foundation, San Antonio, Texas, and Clinical Professor of Medicine, Division of Medical Oncology at The University of Texas, Health Science Center at San Antonio, San Antonio, Texas; Institute for Drug Development, San Antonio, Texas. From the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX; Introgen Therapeutics Inc, Houston, TX From the Institute for Drug Development, Cancer Therapy and Research Center; Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX; and GlaxoSmithKline, Research Triangle Park, NC 13Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; From the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio; The University of Texas Health Science Center at San Antonio, San Antonio; Division of Oncology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX; and Schering-Plough Research Institute, Kenilworth, NJ. From the Institute for Drug Development, Cancer Therapy and Research Center; The University of Texas Health Science Center at San Antonio; and Brooke Army Medical Center, San Antonio; Joe Arrington Cancer Center, Lubbock, TX; and Daiichi Pharmaceutical Corporation, Montvale, NJ. From the Institute for Drug Development at the Cancer Therapy and Research Center; Nuclear Medicine Department, The University of Texas Health Science Center, San Antonio, TX; Indiana University Cancer Center; and Eli Lilly and Company, Indianapolis, IN. 1Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, 1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and 1Institute for Drug Development, Cancer Therapy and Research Center; From the Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio; and Brooke Army Medical Center, San Antonio, TX; and Biochem Pharma Inc, Laval, Canada. From the Institute for Drug DevelopmentCancer Therapy and Research Center and the University of Texas Health Science Center, San Antonio, TX; and Pro-Neuron, Inc, Gaithersburg, MD. 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas; 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, San Antonio, Texas and From the Mayo Clinic, Rochester, MN; Cancer Therapy and Research Institute, University of Texas Health Science Center, San Antonio, TX; and Wyeth Research, Collegeville, PA, Cambridge, MA, and Pearl River, NY 1Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas From The University of Texas Health Science Center at San Antonio and Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone... 1Department of Clinical Research and Regulatory Affairs, ImClone Systems Incorporated, Branchburg, New Jersey and 1Institute for Drug Development, Cancer Therapy and Research Center, and 3The Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas; 1Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas; 1Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas; Departments of From the Fox Chase Cancer Center, Philadelphia, PA; Sidney Kimmel Cancer Center, San Diego; Amgen Inc, Thousand Oaks; and Jonsson Cancer Center, University of California at Los Angeles, Los Angeles, CA; Cleveland Clinic Foundation, Cleveland, OH; Arizona Clinical Research Center, Tucson, AZ; Cancer Therapy and Research Center Institute for Drug Development, San Antonio, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN. 1Cancer Therapy and Research Center, Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy and Research Center and 2Brooke Army Medical Center, San Antonio, Texas; and 3PharmaMar Clinical R&D, Colmenar Viejo, Madrid, Spain From the Cancer Therapy and Research Center, Institute for Drug Development; The University of Texas Health Science Center, San Antonio, TX; Cognigen Corp, Buffalo, NY; and ARIAD Pharmaceuticals Inc, Cambridge MA Authors' Affiliations: 1Division of Medical Oncology and Departments of 2Preventive Medicine and 3Pathology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California; 4Oncology, Merck & Co., Inc., New Jersey; and 5Oncology, Bristol-Myers Squibb Pharmaceuticals Limited; 6Oncology, ImClone Systems, New York, New York From the Institute for Drug Development, Cancer Therapy, and Research Center; The University of Texas Health Science Center at San Antonio; Brooke Army Medical Center, San Antonio, TX; and Enzon Inc., Piscataway, NJ. From the Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio; Brooke Army Medical Center, San Antonio, TX; and Bristol-Myers Squibb, Wallingford, CT. From the Department of PharmacologyFox Chase Cancer Center, Philadelphia, PA; Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, TX; and National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD. From the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX; South Texas Oncology and Hematology, PA, San Antonio, TX; Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX; School of Pharmacy, University of Connecticut, Farmington, CT; and Sugen, Inc, Redwood City, CA. From the Indiana University Medical Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Westlake Comprehensive Cancer Center, Westlake Village, CA; Johns Hopkins Oncology Center, Baltimore, MD; and Emory University, Atlanta, GA. From the Department of Medical Oncology, Erasmus MC–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Institut Claudius-Regaud, Toulouse, France; and the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX From the Institute for Drug Development, Cancer Therapy and Research Center, and The University of Texas Health Science Center at San Antonio, San Antonio; Brooke Army Medical Center, Fort Sam Houston, TX; and Hoffmann-LaRoche, Inc, Nutley, NJ. From the Institute for Drug Development, Cancer Therapy and Research Center, and The University of Texas Health Science Center at San Antonio, San Antonio, TX; and Otsuka America Pharmaceutical, Inc, Palo Alto, CA. From the Institute for Drug Development, Cancer Therapy and Research Center and Brook Army Medical Center, San Antonio, TX; Beth Israel Deaconess Cancer Center, Boston, MA; University of Washington, Seattle, WA; University of Chicago Cancer Research Center, Chicago, IL; Cleveland Clinic, Cleveland, OH; Fox Chase Cancer Center, Philadelphia, PA; UCLA School of Medicine, Los Angeles; and Abgenix Inc, Fremont, CA; and Our Lady of Mercy Cancer Center, New York. Medical College, Bronx, NY From the Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; University Hospital Gasthuisberg, Leuven, Belgium; Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ; Dana-Farber/Partners CancerCare, Boston, MA; Swedish Cancer Institute, Seattle, WA; St Joseph Mercy Hospital, Ann Arbor, MI; Center for Oncology Research and Treatment, Dallas, TX; Rocky Mountain Cancer Center, Denver, CO; Lakeland Regional Cancer Center, Lakeland, FL; and ImClone Systems... Authors' Affiliation: Clinical Affairs Department, ImClone Systems, Inc., Branchburg, New Jersey 2Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; and From the Divisions of Oncology Research and Hematology, Mayo Clinic, and Department of Pharmacology, Mayo Medical School, Rochester, MN; the Adult Leukemia Program and Divisions of Medical Oncology and Pharmacology and Experimental Therapeutics, Johns Hopkins Oncology Center, Baltimore, MD; and the Department of Pharmacology, Yale University Medical School, New Haven, CT. Institute for Drug Development, Cancer Therapy and Research Center, and University of Texas Health Science Center, San Antonio, TX From the University of Colorado at Denver, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; Indiana University Simon Cancer Center, Indianapolis, IN; and ImClone Systems, New York, NY. |
Incoming Links
Total number of triples: 255.